Corcept Therapeutics Incorporated
NASDAQCorcept Therapeutics is climbing hard while short sellers refuse to blink — the stock has gained 31% in a month, yet short interest barely budged. Options traders have flipped from defensive to outright bullish in a matter of days. The put/call ratio collapsed to 0.27, nearly 1.6 standard deviations below its 20-day mean of 0.51, and is at the lowest reading of the past year. Two…
Snapshot as of 27 May 2026
Corcept Therapeutics is climbing hard while short sellers refuse to blink — the stock has gained 31% in a month, yet short interest barely budged. Options traders have flipped from defensive to outright bullish in a…
Corcept Therapeutics enters the week after a strong earnings beat with shorts beating a steady retreat — and a high-profile analyst upgrade arriving just as the stock consolidates those gains. The setup is a study in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CORT — free to start on ORTEX.
Sign up for free →Open CORT on ORTEX